AXIM Biotechnologies (AXIM Biotechnologies) EPS (Diluted) : $-0.03 (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is AXIM Biotechnologies EPS (Diluted)?

AXIM Biotechnologies's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.03.

AXIM Biotechnologies's EPS (Basic) for the three months ended in Mar. 2024 was $-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.03.

AXIM Biotechnologies's EPS without NRI for the three months ended in Mar. 2024 was $-0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.02.

During the past 3 years, the average EPS without NRIGrowth Rate was 23.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 22.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was -7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, AXIM Biotechnologies's highest 3-Year average EPS without NRI Growth Rate was 24.10% per year. The lowest was -300.00% per year. And the median was 16.70% per year.

AXIM Biotechnologies EPS (Diluted) Historical Data

The historical data trend for AXIM Biotechnologies's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AXIM Biotechnologies EPS (Diluted) Chart

AXIM Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-0.10

-0.06

-0.12

-0.04

AXIM Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Diluted)	Get a 7-Day Free Trial															-0.01	-0.02	-	-0.01	-

Competitive Comparison of AXIM Biotechnologies's EPS (Diluted)

For the Biotechnology subindustry, AXIM Biotechnologies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AXIM Biotechnologies's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's PE Ratio distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's PE Ratio falls into.

AXIM Biotechnologies EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

AXIM Biotechnologies's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-8.06	-	0)	/	227.691
	=	-0.04

AXIM Biotechnologies's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-0.292	-	0)	/	261.396
	=	-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

AXIM Biotechnologies (OTCPK:AXIM) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

AXIM Biotechnologies EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of AXIM Biotechnologies's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

AXIM Biotechnologies (AXIM Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AXIM Biotechnologies Inc (OTCPK:AXIM) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

6191 Cornerstone Court, E, Suite 114, San Diego, CA, USA, 92121

Website

https://www.aximbiotech.com

Axim Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, it owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.

Executives

Kurt Phinney	officer: Chief Operating Officer	6914 MAGELLAN WAY, SARASOTA FL 34243
Peter O'rourke	director	C/O NORTHVIEW ACQUISITION CORP., 207 WEST 25TH STREET, 9TH FLOOR, NEW YORK NY 10001
Catalina Valencia	10 percent owner	6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Glycodots, Llc	10 percent owner	6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Juniper & Ivy Corp	10 percent owner	5201 MEMORIAL DRIVE, SUITE 616, HOUSTON TX 77007
Huemoeller John Walter Ii	director	305 SAN ANSELMO AVENUE, SUITE 300, SAN ANSELMO CA 94960
Blake Schroeder	director	5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert L Cunningham	director	5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Timothy Richard Scott	director	5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert Malasek	officer: CFO	PO BOX 235472, ENCINITAS CA 92023
Lekhram Changoer	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Medical Marijuana, Inc.	10 percent owner	12255 CROSTHWAITE CIRCLE, POWAY CA 92064
Van Damme Philip A	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Foundation Sanammad	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
George Anastassov	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022